A New Hampshire patient has achieved a monumental medical milestone by surviving for a record 271 days with a genetically modified pig kidney before successfully transitioning to a human organ. Tim Andrews, a 68-year-old retired grocery store manager from Barrington, received the porcine xenotransplant on January 25, 2025, at Mass General Brigham in Boston, after facing advanced renal failure driven by type 2 diabetes. The pioneering case, detailed in findings published in The Lancet, marks the longest dialysis-free survival following porcine kidney xenotransplantation in a living human and represents the first successful transition from an animal organ to a human donor kidney.
When Andrews and his clinical team initially explored the experimental procedure in late 2024, he understood the grave risks involved but chose to proceed to advance medical science. "I didn’t think I was going to live through it, to be honest. But I wanted to do it for humanity," Andrews told reporters, reflecting on his decision when he felt like a "dead man walking." Operating surgeons, led by Dr. Leonardo Riella, utilized a kidney harvested from a Yucatan miniature pig engineered with 69 genomic modifications to humanize the organ, disguise it from immune attacks, and disable latent viral sequences.
Genetic Engineering and Immunological Management
Overcoming the human immune system's immediate rejection response required extensive genomic engineering of the donor animal. Without modification, a foreign organ would undergo hyperacute rejection, turning dark and clotting within minutes as antibodies and cellular assaults destroy its vasculature. The 69 genomic edits performed on the source pigs strip away specific cell-surface features recognized by human immune systems, insert human camouflage genes to hide the tissue, and disable porcine endogenous retroviruses to safeguard the recipient.
Despite these advanced precautions, maintaining organ function over nearly nine months required active clinical management. Early indications of immune rejection surfaced during Andrews' recovery, but medical teams successfully reversed the reaction by carefully adjusting his immunosuppressive medication regimen. However, after approximately six months, doctors observed progressive inflammation and blood vessel damage within the organ, leading to gradual functional failure without clear evidence of antibody-mediated attack.
The Clinical Bridge to Human Transplants
Medical researchers emphasize that the primary objective of xenotransplantation is not immediate replacement of human organs, but rather functioning as a reliable bridge for patients trapped in the severe global organ shortage. More than 100,000 Americans currently languish on national transplant waiting lists, with the vast majority desperately waiting for a healthy kidney while enduring grueling dialysis sessions that offer limited long-term survival rates.
Andrews' case successfully demonstrated that a porcine kidney can maintain sustained dialysis independence for an extended duration, buying crucial time until a matching human donor becomes available. Following the eventual failure and removal of the pig kidney in October 2025, Andrews required 82 days of dialysis before receiving a human donor kidney in January 2026, which has since functioned perfectly and restored his physical vitality.
Broader Landscape and Future Outlook
This landmark achievement builds upon prior xenotransplantation milestones at Massachusetts General Hospital, where the world's first pig-to-human kidney transplant was performed in 2024 on Richard "Rick" Slayman, who survived for 52 days before passing away from unrelated cardiac complications. In another parallel case, Towana Looney survived for 130 days with a pig kidney before removal due to rejection, keeping her alive on dialysis while awaiting a human donor.
Clinical leaders remain optimistic that continued refinement will accelerate the timeline for xenotransplantation to enter mainstream medicine. While initial projections suggested a decade before porcine organs became viable clinical alternatives, recent breakthroughs have shortened estimated horizons to five years or less. Andrews, now relishing everyday activities like swimming, fishing, and spending time with his family, expressed hope that future patients will benefit from the data gathered during his historic procedure.
